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A B S T R A C T
Aim: To assess the efficacy of infliximab in ulcerative colitis (UC) patients who had 
failed therapy with adalimumab or golimumab. 
meThodS: Retrospective analysis of prospectively acquired data of all anti-TNF na-
ive patients with moderate to severe UC who received adalimumab or golimumab 
in 4 tertiary referral centres. Patients with primary non response or secondary loss 
of response to adalimumab or golimumab received therapy with infliximab. Clini-
cal response and remission rates were assessed at week 14 and 54 after initiation of 
infliximab. 
ReSulTS: Between September 2015 and September 2017, 29 of 58 (50%) anti-TNF 
naive patients with moderate to severe UC failed therapy with adalimumab (n=38) 
or golimumab (n=20). Twenty one of 29 (72.4%) patients were primary non respond-
ers and 8 (27.6%) patients lost response to adalimumab or golimumab. All these 29 
patients received infliximab, while 15 (51.7%) were on concomitant azathioprine ther-
apy. Eighteen (62.1%) and 10 (34.5%) patients showed clinical response and clinical 
remission at week 14 respectively, while 14 (48.3%) patients were on clinical remission 
at week 54 after initiation of infliximab. Azathioprine co-administration at the start 
of infliximab was associated with a greater proportion of patients achieving clinical 
remission at week 54 (10 of 15 patients on combination therapy vs 4 of 14 patients on 
infliximab monotherapy, p=0.04).
ConCluSionS: A significant proportion of anti-TNF naive patients with moderate to 
severe UC who have failed 1st course therapy with subcutaneous anti-TNF agents can 
achieve clinical response and/or remission with 2nd course therapy with infliximab.
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i n T R o d u C T i o n
Biologics against tumor necrosis factor (anti-TNF) have 
revolutionized the management of moderate-to-severe ulcera-
tive colitis (UC), by inducing and maintaining clinical response 
and remission and decreasing the rates of complications, hos-
pitalizations and colectomy.1-3 In European Union countries, 3 
anti-TNF agents are commercially available for the treatment 
of moderate-to-severe UC, namely infliximab (IFX), which 
is administered intravenously and adalimumab (ADL) and 
golimumab (GLM), which are administered subcutaneously. 
In randomized controlled trials and observational studies all 
these agents have shown efficacy in achieving remission in 
moderate-to-severe UC, but only IFX has been studied and 
proved efficacious in acute severe i.v. steroid-refractory UC, 
respectively.4-9
Despite proven efficacy, approximately one third of the 
patients with active UC do not respond to induction treatment 
with anti-TNF agents (primary non responders), whereas an-
other one third of initial responders lose response over time 
(secondary loss of response).10 Although failure to respond to 1st 
course anti-TNF agent does not imply a class failure, it decreases 
significantly the effectiveness of the 2nd course anti-TNF agents.11 
Thus, selection of and appropriate use of the most effective 
anti-TNF agent for the “first hit” is important. Indeed, tradition 
and experience have established the role of IFX as the most 
appropriate 1st course anti-TNF agent in UC.12-16 However, in 
the absence of head-to-head, randomized, controlled trials, the 
selection of the appropriate anti-TNF agent for the treatment 
of moderate-to-severe UC in real life relies also upon patients’ 
preferences and convenience and the necessity to reduce the 
workload of infusion units. This has led to an increased use of sc 
administered anti-TNF agents for 1st course anti-TNF treatment 
in ambulatory UC patients with moderate to severe disease. 
Whether primary non-response or secondary loss of response to 
ADL or GLM can be effectively re-captured with second course 
anti-TNF therapy with IFX has not been adequately studied. 
We, therefore, aimed at assessing the effectiveness of IFX as 
second course anti-TNF treatment in patients with moderate-
to-severe UC, who did not respond primarily or developed 
secondary loss of response to ADL or GLM. 
m e T h o d S
This is a multicentre retrospective study which analysed 
prospectively acquired data on consecutive anti-TNF naïve 
patients with moderate-to-severe UC, who were treated with 
ADL or GLM as first course anti-TNF therapy. Eligible were 
patients older than 18 years, with moderate-to-severe UC, di-
agnosed according to standard criteria,17 with disease duration 
of at least 6 months prior to treatment, naive to anti-TNFs. 
Patients were not included in the study if they had active 
infection, latent or active tuberculosis, a history of previous 
demyelinating disorders or malignancies, severe heart failure, 
previous colectomy or any poorly controlled co-morbidity. 
Pregnant or breast feeding female patients were also excluded. 
The study was conducted in 4 major tertiary referral IBD 
centres covering a large geographical area in Greece. UC was 
defined as extensive, left-sided or proctitis according to the 
Montreal classification,18 while severity was graded according 
to the total Mayo score.19 Eligible patients had active UC with 
a Mayo score of 6 to 9 points and more than 1 point in each 
of the 4 sub-scores (scores can range from 0 to 12, with higher 
scores indicating more severe disease activity). Previous and 
current use of corticosteroids and any immunosuppressive 
agent was recorded. 
Reasons for ADL or GLM discontinuation included pri-
mary non response and secondary loss of response. Primary 
non response was defined as a failure to achieve a decrease 
from baseline in the total Mayo score of at least 3 points and 
at least 30%, with an accompanying decrease in the sub-score 
for rectal bleeding of at least 1 point or an absolute sub-score 
for rectal bleeding of 1. Secondary loss of response was defined 
as reappearance of symptoms of active UC in association with 
elevation of CRP at any time period between week 14 and 54 
of ADL or GLM maintenance therapy, in the absence of any 
infection, such as clostridium difficile or cytomegalovirus. 
Patients with primary non response or secondary loss of 
response to ADL or GLM received the classical IFX induction 
and maintenance therapy, i.e. 5 mg/Kg at weeks 0, 2 and 6 and 
then every 8 weeks until week 54. During this period, patients 
were assessed at each IFX infusion with physical examination, 
laboratory tests, partial Mayo score and a check for adverse 
events. Extra visits were arranged at any time recurrence of 
symptoms suggested a relapse of UC. Endoscopic assessment 
was performed at baseline, at weeks 14 and 54, and at any time 
recurrence of symptoms suggested a flare of disease.
Clinical response to IFX induction was assessed with the 
total Mayo score at week 14 and defined as a decrease from 
baseline of at least 3 points and at least 30% percent from 
baseline, with an accompanying decrease in the sub-score for 
rectal bleeding of at least 1 point or an absolute sub-score for 
rectal bleeding of 1. Clinical remission to IFX was assessed at 
week 14 and 54 of IFX treatment and was defined as a Mayo 
score of ≤2 with no individual sub-score >1. 
S T A T i S T i C A l  A n A ly S i S
Statistical analysis of initial response and remission rates 
was limited to descriptive statistics. The X2 test or Fisher’s 
exact test were used for comparing qualitative variables and 
results were reported as numbers and percentages. Analyses 
were performed using SPSS software version 17.0 (Chicago, 
Illinois, USA) and a two-tailed p-value of <0.05 was consid-
ered statistically significant.
26
HOSPITAL CHRONICLES 15(1), 2020
The study was approved by the Ethics committee of the 
participating Institutions; all patients gave written informed 
consent. 
R e S u l T S
Between 1st September 2015 and 30th September 2017, 58 
anti-TNF naive UC patients with moderate-to-severe disease 
were treated with ADL (n=38) or GLM (n=20) in the partici-
pating centres. The baseline characteristics of the patients are 
summarised in table 1. All patients had received corticosteroids 
at some point in time. At initiation of anti-TNF treatment, 
all patients were receiving oral and/or rectal mesalazine, 12 
(20.7%) patients were receiving oral corticosteroids and 36 
(62.1%) patients were receiving thiopurines (35 azathioprine 
and 1 mercaptopurine). 
Overall, 21 of 58 (36.2%) patients showed primary non-
response to ADL (n=13, 61.9%) or GLM (n=8, 38.1%) and 
another 8 patients (13.8%) developed secondary loss of re-
sponse to ADL (n=7, 87.5%) or GLM (n=1, 12.5%). Among 
the 7 patients with secondary loss of response to ADL, ineffec-
tive dose escalation to 40mg every week had been performed 
in 4 patients prior to cessation of therapy. 
Thus, 29 patients were started on IFX. The baseline char-
acteristics of these patients are summarised in table 2. None 
of the patients was receiving corticosteroids at the time of IFX 
initiation, while all 29 were receiving oral and/or rectal mesala-
zine and 15 (51.7%) patients were also receiving azathioprine. 
Eighteen (62.1%) patients were responders to IFX induc-
tion therapy at week 14, while 10 (34,5%) and 14 (48.3%) 
patients were in clinical remission at week 14 and 54 respec-
tively (Fig. 1). The median full Mayo score at baseline was 9 
(Interquantile range 2, Fig. 2) versus 5 (Interquantile range 
5, Fig. 3) at week 14 and 3 (Interquantile range 3.5, Fig. 4) 
at week 54. At baseline, 26 (89.6%) patients had an elevated 
C-reactive protein (CRP >5mg/L), while the number of pa-
tients presenting with CRP >5mg/L at weeks 14 and 54 were 
13 (44.8%) and 7 (24.1%) respectively. 
The proportion of patients who were either non-responders 
(11 out of 21, 52.4%) or lost response to ADL or GLM (3 out 
of 8, 37.5%) and achieved clinical remission after 2nd course 
anti-TNF therapy with IFX, at week 54, was not significant 
FiGuRe 1. Proportion of patients treated with Infliximab 
achieving clinical response at week 14 and clinical remission at 
weeks 14 and 54.
Table 1. Baseline characteristics of patients receiving 
subcutaneous anti-TNF




Age (years), median (range) 40.6 (19-78)
Disease extent, n (%) E1 = 1 (1.7%)
E2 = 32 (56.1%)
E3 = 25 (43.1%)
Disease duration (months), 
median (range) 
38.6 (6-72)
Smokers/non-smokers, n (%) 19 (32.7%)/39 (67.2%)
Corticosteroids, n (%) 12 (20.7%)
5-ASA, n (%) Per os = 58 (100%)
Per rectum = 44 (75.8%)
Immunosuppressants, n (%) Azathioprine = 35 (60.3%)
6-mercaptopurine = 1 (1.7%)
Table 2. Baseline characteristics of patients receiving 
Infliximab
Males/females, n (%) 16 (55.2%) /13 (44.8%)
Age (years), median (range) 38.9 (21-69)
Disease extent, n (%) E2 = 18 (62.1%)
E3 = 11 (37.9%)
Disease duration (months), 
median (range)
34.8 (6-67)
Smokers/non-smokers, n (%) 8 (27.5%) /21 (72.4%)
Corticosteroids, n (%) 0 (0%)
5-ASA, n (%) Per os = 29 (100%)
Per rectum = 19 (65.5%)
Immunosuppressants, n (%) Azathioprine = 15 (51.7%)
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(p=0.47). However, concomitant treatment with azathioprine 
at initiation of IFX was associated with a greater proportion 
of clinical remission at week 54 (10 of 15 patients receiving 
azathioprine achieved clinical remission vs 4 of 14 patients on 
IFX monotherapy, p=0.04).
Seven of the 11 (37.9%) patients who did not show a 
satisfactory clinical response to IFX at week 14, received a 
dose escalation (10mg/Kg every 8 weeks) for maintenance; 4 
patients responded to dose intensification, but 2 patients were 
switched to vedolizumab and 1 patient opted to colectomy. 
IFX administration was safe and no serious adverse reac-
tions were seen. One patient developed a psoriasiform rash 
at his palms, which responded to local treatment and IFX 
administration was not discontinued. 
d i S C u S S i o n
In this study, anti-TNF naive patients with UC of moder-
ate-to-severe activity who failed 1st course treatment with the 
subcutaneously administered anti-TNF agents ADL and GLM 
could be successfully recaptured with 2nd course therapy with 
IFX. Indeed, among the 29 patients who developed primary 
non response or secondary loss of response to ADL or GLM, 
18 (62.1%) and 10 (34.5%) patients showed clinical response 
FiGuRe 2. Median full Mayo score and interquantile range at 
baseline for patients receiving Infliximab.
FiGuRe 3. Median full Mayo score and interquantile range at 
week 14 for patients receiving Infliximab.
FiGuRe 4. Median full Mayo score and interquantile range at 
week 54 for patients receiving Infliximab.
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and clinical remission at week 14 respectively, while 14 (48.3%) 
patients were on clinical remission at week 54 after initiation 
of IFX. Continuing azathioprine at initiation of IFX was as-
sociated with a significantly greater proportion of patients 
achieving clinical remission at week 54. 
Confusion regarding the position of biologics in treatment 
algorithms for moderate-to-severe UC has increased due to 
the advent of additional anti-TNF molecules, biologics which 
target non anti-TNF inflammatory pathways, the approval 
of biosimilars to anti-TNF originators and approval of small 
molecules.20 Studies based on propensity score matching of 
patients treated with different class biologics cannot deliver 
a robust proposal for selecting one class of biologic over the 
other and until prospective, randomized, head-to-head studies 
are available the selection of the most appropriate treatment 
for the individual patient relies on rather arbitrary criteria, such 
as physician experience and preferences, patient preferences 
and cost of treatment. However, it has been quite clear that 
inappropriate selection and use of the first biologic agent for 
the individual patient undermines the future course of disease 
and the response to subsequent biologics.11-16
Accumulated data from randomized controlled trials, real-
life studies and data from meta-analyses provide the best long 
term evidence that all approved anti-TNF agents are effective 
in inducing and maintaining corticosteroid free remission and 
mucosal healing in patients with moderate-to-severe UC.20-22 
In the ACT 1 and ACT 2, IFX achieved significantly higher 
rates of clinical remission over placebo at week 8 of treatment 
(35% and 31% vs 15% and 6% in ACT 1 and ACT 2 studies, 
respectively) and sustained remission was achieved during the 
entire study period in 20% of patients on IFX vs 5% of patients 
on placebo.4 Real life data from major referral centres have 
confirmed the results of randomized, controlled trials.23,24 In 
the ULTRA 1 and 2 randomized, controlled trials the classical 
dosing regimen of ADL (160/80mg subcutaneously at weeks 
0 and 2, followed by 40mg subcutaneously every 2 weeks) 
achieved and maintained significantly higher annual rates of 
remission over placebo (17% vs 9%, respectively).6,7 Difference 
in remission rates was even higher for biologic naive patients 
(22% vs 10% for ADL and placebo treated patients, respective-
ly). Finally, in the PURSUIT trials, GLM resulted in a greater 
proportion of patients achieving clinical remission at week 6, 
following induction therapy with 200/100mg or 400/200mg 
compared to placebo (51% and 55% vs 30% respectively).8 
In the PURSUIT-M, 464 patients with moderate-to-severe 
UC, who had responded favourably to GLM in the induction 
trial demonstrated greater efficacy over placebo at maintain-
ing clinical remission at week 54 (42% vs 27% respectively).9 
However, with the exception of the dominant role of IFX as 
rescue therapy for iv corticosteroid refractory UC,25 the crucial 
selection of the most appropriate of the available anti-TNF 
agents for the first treatment of ambulatory patients with 
moderate-to-severe UC remains, as said before, arbitrary.26,27
A recent meta-analysis of eight randomized controlled tri-
als in IBD patients who have failed first line biologic therapy 
with an anti-TNF agent stratified response to second-line 
biologic by reason for discontinuing anti-TNF therapy [primary 
non-response vs. secondary loss of response vs. intolerance].12 
This study revealed that patients with primary non-response to 
atni-TNF therapy were 24% (RR, 0.76 [0.61– 0.96]) and 27% 
(RR, 0.73 [0.56–0.97]) less likely to achieve remission with 
second-line biologics compared to patients who discontinued 
anti-TNF for intolerance or secondary loss of response to first 
line anti-TNF, respectively. Another systematic review with 
meta-analysis focusing on the efficacy of a second anti-TNF in 
IBD patients, whose previous anti-TNF treatment has failed, 
identified only six studies in UC, in which all patients had re-
ceived IFX and switched to ADL, with remission rates varying 
from 0 to 50%.11 Thus, we think that our study is the first in 
the literature to report on the clinical response and remission 
rates of patients with moderate-to-severe UC receiving IFX 
after failure of ADL or GLM. According to our results, IFX 
appears to be effective in this setting, independent of the 
reason for failure of ADL or GLM (primary non response or 
secondary loss of response). 
In our study azathioprine co-administration at the ini-
tiation of treatment with IFX was associated with a greater 
proportion of patients achieving clinical remission at week 
54. This effect may be due to a higher synergistic effect of 
azathioprine with IFX than with ADL or GLM, but also 
to interference of azathioprine in pharmocodynamics and 
pharmacokinetics of IFX, such as preventing anti-drug an-
tibodies by down-regulating the immunogenic effect of IFX 
(a chimeric antibody of proven higher immunogenicity than 
ADL or GLM), decreasing the metabolism of IFX, increasing 
the recycling rates of IFX via the neonatal FCn receptor, by 
reducing the production of endogenous IgG, etc.28 Higher 
rates of efficacy of the combination therapy with IFX and 
azathioprine have been documented in the SONIC trial in 
biologic naive patients with Crohn’s disease,29 as well as in the 
UC-SUCCESS trial in patients with UC.30 Following these 
results, in many centres therapy is initiated with both com-
bined thiopurine and anti-TNF administration, while thiopu-
rines are then discontinued after 6 months in the setting of 
clinical and biochemical remission, a strategy which has been 
supported in the literature mainly for patients with Crohn’s 
disease.31 Although it could be argued that adding an anti-
TNF biologic to pre-existing treatment with azathioprine does 
not increase the short term efficacy of the anti-TNF agent, 
as was shown in several post-hoc analyses of randomized 
controlled trials with IFX, ADL or GLM,32 this scenario is 
entirely different from what we have observed in this study, 
in which IFX has replaced a failing first line subcutaneously 
administered anti-TNF agent. On the other hand we can-
not exclude a chance observation due to the small number 
of patients on combination IFX plus azathioprine therapy. 
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Our study has several limitations, mainly its retrospective 
design and lack therapeutic drug monitoring. However, we 
think that there are also strong points, since all data were 
acquired prospectively, treatment in the participating centres 
followed strict evidence-based rules, the study population was 
homogenous as regards ethnicity, social class and residence, 
while the total Mayo score with colonoscopy was used to docu-
ment response to therapy. 
In conclusion, a significant proportion of anti-TNF naive 
patients with moderate to severe UC who have failed 1st course 
therapy with subcutaneous anti-TNF agents can achieve clini-
cal response and/or remission with 2nd course therapy with IFX.
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